The Maynards have given tissue samples to researchers at Rambam Hospital in Israel to try to figure out why these mutations occur, and that research has led to a recent breakthrough. The researchers have identified the gene responsible for Maynard's disorder -- which could help them determine how to treat the condition, and could have implications for skin cancer research as well.
While treatment is extremely far off, Maynard and her family are heartened by the possibility.
Radley has something to look forward to as well.
Apoxis, a Swiss company, has created a gene therapy to correct many issues involved with his disorder, and the company hopes to begin human trials in two years. If the trials are successful, this therapy could help improve development of teeth, hair and sweat glands for people that suffer from this E-D.
For More Information on Ectodermal Dysplasia: